Ropes & Gray advised Accutar Biotechnology in a strategic partnership with Evommune focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases. The collaboration will leverage Accutar’s AI platform as well as Evommune’s experience in the design and development of oral small molecule therapies against targets that are the cause of chronic immune inflammatory diseases. The collaboration was announced on November 28. Financial terms were not disclosed.
Accutar is a clinical stage biotechnology company focused on AI-powered drug discovery. The company has a hybrid approach of computational drug design and wet lab validation.
The Ropes & Gray team included life sciences transactions partner Hannah England and intellectual property transactions associate Sameer Desai.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.